Free tool
FAERS Monitor: Tecentriq Hybreza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761347 or its brand name (Tecentriq Hybreza, Atezolizumab and Hyaluronidase-Tqjs). Reports on generic versions are filed under their own applications.
Reports
24
Serious
5
21% of reports
Hospitalization
1
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain4
- no adverse event4
- blister2
- malaise2
- pain2
- product administered at inappropriate site2
- product storage error2
- abdominal discomfort1
- burning sensation1
- death1
- deep vein thrombosis1
- dizziness1
- dyspnoea1
- fatigue1
- flushing1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 4 |
| 2025 | 10 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administered at inappropriate site | 2 | 95.6 | 25.4 | 105 |
| blister | 2 | 31.2 | 8.3 | 32 |
| product storage error | 2 | 20.0 | 5.3 | 20 |
| no adverse eventSignal | 4 | 19.3 | 7.9 | 53 |
| deep vein thrombosis | 1 | 13.5 | 2.0 | 2 |
| burning sensation | 1 | 12.5 | 1.8 | 2 |
| injection site painSignal | 4 | 11.4 | 4.7 | 29 |
| flushing | 1 | 8.6 | 1.3 | 1 |
| abdominal discomfort | 1 | 5.2 | 0.8 | 1 |
| malaise | 2 | 4.0 | 1.1 | 2 |
| pain | 2 | 2.9 | 0.8 | 1 |
| dizziness | 1 | 1.8 | 0.3 | 0 |
| dyspnoea | 1 | 1.5 | 0.2 | 0 |
| fatigue | 1 | 1.1 | 0.2 | 0 |
| death | 1 | 1.0 | 0.1 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.